Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Links shared publicly online about this topic.

1,390
total visits

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of I

View full resource at news-medical.net

Tags: Flu, Flu Medication, H1N1, Drug, Pharma, Relenza, News